Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (81-90 of 259) with videos related to

Pageof 26
Sort By:
The Lancet. Oncology|April 23, 2021
Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancerMaria Alice Franzoi, Elisa Agostinetto, Marta Perachino, et al.
ESMO Open|November 15, 2018
Risk factors for the development of brain metastases in patients with HER2-positive breast cancerChristian Maurer, Lorraine Tulpin, Michel Moreau, et al.
Cancers|November 11, 2022
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast CancerElisa Agostinetto, Flavia Jacobs, Véronique Debien, et al.
Clinical Breast Cancer|November 9, 2021
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current EvidenceBenedetta Conte, Davide Soldato, Maria Grazia Razeti, et al.
Breast Care (Basel, Switzerland)|January 2, 2023
HER2-Low Breast Cancer: Where Are We?Chiara Molinelli, Flavia Jacobs, Caterina Marchiò, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapyIvana Bozovic-Spasojevic, Lieveke Ameye, Marianne Paesmans, et al.
ESMO Open|February 22, 2020
Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trialsDaniel Eiger, Maria Alice Franzoi, Noam Pondé, et al.
European Journal of Cancer (Oxford, England : 1990)|April 27, 2025
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomitingKarin Jordan, Evandro de Azambuja, María Ángeles García Del Barrio, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2023
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysisDiogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, et al.
International Journal of Radiation Oncology, Biology, Physics|October 27, 2019
Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA TrialJoseph Abi Jaoude, Evandro de Azambuja, Maha Makki, et al.
Pageof 26

Showing results (81-90 of 259) with videos related to

Sort By:
Pageof 26
The Lancet. Oncology|April 23, 2021
Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancerMaria Alice Franzoi, Elisa Agostinetto, Marta Perachino, et al.
ESMO Open|November 15, 2018
Risk factors for the development of brain metastases in patients with HER2-positive breast cancerChristian Maurer, Lorraine Tulpin, Michel Moreau, et al.
Cancers|November 11, 2022
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast CancerElisa Agostinetto, Flavia Jacobs, Véronique Debien, et al.
Clinical Breast Cancer|November 9, 2021
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current EvidenceBenedetta Conte, Davide Soldato, Maria Grazia Razeti, et al.
Breast Care (Basel, Switzerland)|January 2, 2023
HER2-Low Breast Cancer: Where Are We?Chiara Molinelli, Flavia Jacobs, Caterina Marchiò, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapyIvana Bozovic-Spasojevic, Lieveke Ameye, Marianne Paesmans, et al.
ESMO Open|February 22, 2020
Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trialsDaniel Eiger, Maria Alice Franzoi, Noam Pondé, et al.
European Journal of Cancer (Oxford, England : 1990)|April 27, 2025
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomitingKarin Jordan, Evandro de Azambuja, María Ángeles García Del Barrio, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2023
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysisDiogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, et al.
International Journal of Radiation Oncology, Biology, Physics|October 27, 2019
Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA TrialJoseph Abi Jaoude, Evandro de Azambuja, Maha Makki, et al.
Pageof 26